Stocktoria

Caribou Biosciences, Inc. CRBU

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-07-23

Caribou Biosciences, Inc. statistics & valuation

Market cap$166.6M
P / S14.9×
P / B1.4×
Net margin-1327.4%
Return on equity-121.2%
FCF margin-1006.8%
Return on capital-98.9%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-277.60% -697.30% -717.80% -296.10% -1491.90% -1327.40% 202020212022202320242025
Gross margin (%)
202020212022202320242025
Operating margin (%)
-292.20% -697.80% -768.20% -336.60% -1667.20% -1329.40% 202020212022202320242025
Return on equity (%)
-17.30% -33.00% -27.70% -58.90% -121.20% 202020212022202320242025
Shares outstanding
9.7M 60.3M 61.0M 88.4M 92.4M 95.1M 202020212022202320242025
Net debt ($)
202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-95.20% -15.10% -26.60% -23.60% -47.60% -84.50% 202020212022202320242025
Free cash flow margin (%)
-271.30% -360.90% -703.30% -304.30% -1431.70% -1006.80% 202020212022202320242025
Debt / equity (×)
202020212022202320242025
EPS ($)
-$2.11 -$1.64 -$1.38 -$1.65 -$1.59 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-1329.4%-1667.2%-336.6%-768.2%-697.8%-292.2%
Net margin-1327.4%-1491.9%-296.1%-717.8%-697.3%-277.6%
FCF margin-1006.8%-1431.7%-304.3%-703.3%-360.9%-271.3%
Return on assets-84.5%-47.6%-23.6%-26.6%-15.1%-95.2%
Return on equity-121.2%-58.9%-27.7%-33.0%-17.3%146.4%
Current ratio5.717.1611.979.2515.151.96

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.